The Importance of Vendor Selection
Regarding vendor selection in support of allogeneic CAR-T therapy specifically, Gregory Opiteck, Ph.D., VP Head of Translational Sciences at Allogene Therapeutics covers top challenges, best practices, and expectations for the short term.
VIEW THE VIRTUAL EVENT! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online X
Subscribe to Bioprocess Online